Scott T. Aaronson, MD

Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System, Baltimore, Maryland

  • 10Articles
  • 91.4KReads
  • 2008–2026Active
  • 83Collaborators
  • 273Citations

About

Scott T. Aaronson, MD, is affiliated with the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt Health System in Baltimore, Maryland. His publications from 2008 to 2026 focus on major depressive disorder, suicide, anxiety, bipolar disorder, posttraumatic stress disorder, psychedelics, and psychotherapy. His research includes studies on vagus nerve stimulation, psilocybin, transcranial magnetic stimulation, and pharmacologic treatments such as zuranolone and olanzapine. Aaronson frequently collaborates with co-authors Harold A. Sackeim, A. John Rush, Charles R. Conway, David L. Dunner, and Brian J. Mickey.

Publications

JCP
Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report
Original Research ▶ Video

Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report

July 8, 2026

Findings suggest that active VNS reduces suicidal ideation (SI) and potentially induces SI remission among participants with chronic TRD and baseline SI.
, , , et al
JCP
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation
Original Research ▶ Video

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation

May 13, 2026

A single psilocybin dose with psychological support was associated with rapid, large, and durable reductions in suicidal ideation and depressive symptoms.
, , , et al
JCP
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
, , , et al
JCP
The Long Road Toward Equitable MDMA Treatment in the United States
Commentary

The Long Road Toward Equitable MDMA Treatment in the United States

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.
,
JCP
Pilot Study of High Frequency TMS for Bipolar Depression
Original Research

Pilot Study of High Frequency TMS for Bipolar Depression

May 20, 2024

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.
, , , et al
JCP
Long-Term Safety and Efficacy of Zuranolone in MDD
Original Research

Long-Term Safety and Efficacy of Zuranolone in MDD

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
, , , et al
JCP
TMS in Anxious Depression
Original Research

TMS in Anxious Depression

January 11, 2023

Patients with anxious depression tend to have more severe depressive symptoms. This study examined the effects of transcranial magnetic stimulation in these patients.
, , , et al
JCP
Original Research

VNS Improves Quality of Life in Depression

August 21, 2018

Vagus nerve stimulation (VNS) treatment has been shown to be efficacious in treatment-resistant depression (TRD). Can VNS treatment lead to improvements in quality of life in patients with TRD...
, , , et al
JCP
Original Research

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

September 16, 2014

, , , et al
JCP
Original Research

Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study

November 30, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe